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Introduction.We designed this study to evaluate how coagulation parameters are changed in metastatic colorectal cancer (mCRC)
patients treated with bevacizumab, irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI). Methods. A total of 48 mCRC patients
who initially received bevacizumab with FOLFIRI were eligible for this study. Thirty-four patients were analyzed at baseline and
on the 4th, 8th, and 12th cycles of chemotherapy. Results.There were 19 male and 15 female patients. Baseline characteristics of the
groups were similar, but women had better overall survival than men (14 months versus 12 months, 𝑃 = 0.044). D-dimer levels
decreased significantly after the 12th cycle compared with baseline in men but not in women. Men and women had increased levels
of serum fibrinogen at the early cycles, but these increased fibrinogen levels continued after the 4th cycle of chemotherapy only
in women. In addition, serum fibrinogen levels did not significantly change, but aPTT levels decreased in men. Discussion. The
major finding of this study is that bevacizumab-FOLFIRI chemotherapy does not promote changes in the coagulation system. If
chemotherapy treatment and the possible side effects of FOLFIRI-bevacizumab treatment are well managed, then alterations of the
coagulation cascade will not have an impact on overall survival and mortality.
1. Introduction
Bevacizumab is typically used in combination with fluoropy-
rimidine-based chemotherapy for the treatment of patients
with metastatic colorectal cancer (mCRC) [1]. In a pivotal
phase III trial of first-line mCRC, bevacizumab in com-
bination with standard irinotecan/fluorouracil (FOLFIRI)
chemotherapy increased tumor response rate by 10% and
significantly lengthened the overall survival [1, 2]. In the
bevacizumab arm, the patients had an increased incidence
of thrombotic events compared with the control arm (19.4%
versus 16.2%, resp.), but this result was not significant [1].
In a meta-analysis, a total of 7956 patients diagnosed with
many types of solid tumors from 15 randomized trials were
identified. The authors revealed that patients treated with
bevacizumab had a statistically significant increased risk
of venous thromboembolic events (VTEs), with an RR of
1.33 (95% CI, 1.13–1.56, 𝑃 < 0.001) compared with the
controls [3]. Hurwitz et al. reported a meta-analysis of 6,055
patients in 10 randomized studies [4]. This study concluded
that the addition of bevacizumab to chemotherapy did not
significantly increase the risk of VTEs versus chemotherapy
alone. The risk for VTEs was attributed to tumor and host
factors [4]. Epistaxis, hemoptysis, hematemesis, gastroin-
testinal bleeding, vaginal bleeding, and brain hemorrhage
have been reported as hemorrhagic toxicities associated
with bevacizumab [5]. These controversial findings open
the possibility that factors other than bevacizumab, such as
drugs, cancer, age, gender, or comorbidities, can cause VTEs.
Therefore, we designed this study to evaluate how coagulation
parameters, such as the international normalized ratio (INR),
activated partial thromboplastin time (aPTT), and fibrinogen
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2. Materials and Methods
A total of 48 metastatic colorectal cancer patients who had
initially received bevacizumab combined with the FOLFIRI
regimen were eligible for the study. The study was conducted
in the Medical Oncology Clinic of the Bulent Ecevit Univer-
sity School of Medicine between the period of May 2010 and
May 2013. Patients with a previous history of hematological
disease, those who have been taking anticoagulant therapy,
and those with chronic disease, such as liver cirrhosis or
renal failure, were excluded from the study. During the
bevacizumab treatment period, all patients who had Grade
3-4 bleeding were excluded from the study. Written and
verbal consents were obtained from all the patients for
chemotherapy and study enrollment. Treatment responses
were measured between every 2 and 3 months. If a patient
progressed or discontinued bevacizumab for any reason (e.g.,
bleeding, intestinal perforation, and metastasectomy), he or
she was excluded from the study. At the end of the study, a
total of 34 patients were included and analyzed.
2.1. Drug Administration. All patients received the following
treatment regimen: bevacizumab 5mg/kg IV combined with
irinotecan 180mg/m2 IV (Day 1), leucovorin 400mg/m2
IV (Day 1), and 5-fluorouracil (400mg/m2 IV bolus and
then 2400mg/m2 continuous infusion 46 h) IV, once every
2 weeks for 12 cycles. All measurements were repeated at
baseline and on the 4th, 8th, and 12th cycles of chemotherapy.
Chemotherapy was continued beyond the 12th cycle for
patients who had a partial response or stable disease.
2.2. Sample Collection. Blood samples were collected before
drug administration at baseline and on Day 1 of chemother-
apy of the 4th, 8th, and 12th cycles using a 19-gauge needle
under minimum stasis. Platelet counts were analyzed using
a Beckman Coulter Gen-S (SM, USA) automated blood
counting device.
The conventional coagulation parameters, such as the
international normalized ratio (INR), activated partial
thromboplastin time (aPTT), fibrinogen, and D-dimer, were
measured using a fully automated STA compact device from
Diagnostica Stago.
2.3. Statistical Analysis. Treatment outcomes were esti-
mated as response rate (RR), disease control rate, OS, and
progression-free survival (PFS). OS was defined as the time
between the date of metastatic disease diagnosis and the date
of death from any cause. PFS was defined as the time from
the date of metastatic disease diagnosis to the date of disease
progression or death from any cause.
Overall survival was calculated using the Kaplan-Meier
method and the log-rank test. 𝑃 < 0.05 was considered to be
significant.The appropriateness of data to normal ranges was
controlled using the Shapiro-Wilk test. Data were analyzed
using the two-way ANOVA and nonparametric tests. Data in
the tables are presented as the mean and standard error (SE)
or median and interquartile range (IR) of data. A probability
value of less than 0.05 was considered to be statistically
significant.
3. Results
In this study, there were 19 male and 15 female patients diag-
nosedwithmCRC.Themean age of womenwas 60.1 (±7) and
that ofmenwas 61.5 (±9.9); therewas no significant difference
between the groups (𝑃 = 0.59). Baseline characteristics of
the groups are shown in Table 1. All parameters, except OS,
had no statistical significance. Women had greater OS than
men.Men hadmore liver and lungmetastases comparedwith
women, but the difference was not significant (15 versus 9,
𝑃 = 0.7).
Results of laboratory parameters at baseline and on Day 1
of the 4th, 8th, and 12th cycles are presented in Figure 1. Delta
values were defined as the differences between the baseline
and each of the following cycles: 4th, 8th, and 12th. D-dimer
levels decreased significantly after the 12th cycle compared
with the baseline in men but not in women. Both men and
women have increased levels of serum fibrinogen at the early
cycles, but increased fibrinogen levels continued after the 4th
cycle of chemotherapy only inwomen.Conversely, fibrinogen
levels and serum aPTT levels decreased in men but not in
women. Serum INR levels did not change significantly in the
first eight cycles of chemotherapy in both men and women.
However, after the 12th cycle, INR levels increased signifi-
cantly in women. This increase was statistically significant
but without clinical meaning. Women have a higher risk of
anemia than men in the early stages of treatment because
their Hb levels decreased from 12.7 to 12.1, whereas there was
no decrease detected in men. Cox regression analysis did not
find any correlation of laboratory parameters with OS and
PFS.
Some coagulation parameters have differences according
to metastatic sites. In women, baseline fibrinogen levels were
higher in liver metastasis compared with other metastatic
sites, such as bone, peritoneum, and lung (381mg/dL versus
348mg/dL, 𝑃 = 0.007). Additionally, serum baseline PLT
levels were lower in liver metastasis compared with the other
sites (170,000/mm3 versus 262,000/mm3, 𝑃 = 0.007). With
regard to changes in the parameters because of chemotherapy,
Hb levels were different in the groups according to the
metastatic site.There was a significant decrease in the Hb lev-
els in the early period of chemotherapy especially in women.
Dropping Hb levels were more prominent in peritoneal and
bone metastases compared with liver metastasis (0.66 gr/dL
versus 0.35 gr/dL, 𝑃 = 0.04). There was no correlation
between the laboratory parameters and metastatic sites in
men. After the study termination, 1 man and 1 woman (6%
of the study population) had deep vein thrombosis without
pulmonary embolism, and there also was no Grade 3-4
bleeding.
4. Discussion
In this study, we found that FOLFIRI-bevacizumab chemo-
therapy has some changes on coagulation parameters such as
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Table 1: Baseline characteristics of the groups.
Women (minimum–maximum) 𝑛 = 15 Men (minimum–maximum) 𝑛 = 19 𝑃 value
Age, years 60 61.5 0.85
Colon cancer 12 14 —
Rectal cancer 3 5 —
Adenocarcinoma 15 19
Grades 1-2 5 4




Bone 3 4 0.8
Diabetes 3 4
Hypertension 2 5 1
D-dimer (mg/dL) 883 (106–2233) 794 (206–2760) 0.88
Fibrinogen (mg/dL) 382 (330–415) 348 (250–630) 0.73
aPTT (sec) 24 (19–29) 26 (19–29) 0.26
INR 0.93 (0.8–1.06) 1.0 (0.8–1.1) 0.44
Platelet count (×1000mm3) 185 (160–274) 274 (165–468) 0.057
Hemoglobin, gr/dL 12.7 (11.9–13.3) 12.7 (10.7–16) 0.98
Creatinine, mg/dL 0.9 (0.7–1.1) 0.8 (0.5–1.1) 0.17
White blood cell, mm3 5600 (4400–13500) 6600 (3900–11000) 0.46
PFS, months 8 (6–11) 9 (4–14) 0.7
OS, months 14 (10–33) 12 (6–28) 0.044






Baseline 4th 8th 12th
D-dimer, (lg/dL) women
D-dimer, (lg/dL) men
26 25 24 24
24 25 24 25
Baseline 4th 8th 12th
aPTT, (sec.) men
aPTT, (sec.) women
348 398 389 356
382 389 400 402
Baseline 4th 8th 12th
Fibrinogen, (mg/dL) women
Fibrinogen, (mg/dL) men
1 1 0.9 0.96
0.93 0.9 1 1.05
Baseline 4th 8th 12th
INR men
INR women
274 253 252 252
185 221 240 210
Baseline 4th 8th 12th
12.7 13 12.8 13.2
12.7 12.1 12.2 12.5





Figure 1: Results of laboratory parameters at baseline and on Day 1 of cycles 4, 8, and 12.
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decreased D-dimer levels in men, increased fibrinogen levels
in both men and women in the early stage of treatment, and
increased INR in women. Despite these changes, none of
these variables had an effect on OS and/or PFS.
A few small studies have reported changes in coagulation
system markers in response to breast cancer chemother-
apy, and these reports supported the development of a
chemotherapy-induced hypercoagulable state [6]. Kirwan
et al. also reported a well-designed prospective study on the
markers of hemostasis (thrombin-antithrombin (TAT), fib-
rinogen, D-dimer, and platelet count) and functional clotting
assays (prothrombin time (PT) and aPTT and procoagulants
tissue factor (TF), cancer procoagulant (CP), and plasma
vascular endothelial growth factor (pVEGF)), which were
measured before chemotherapy and at 24 h, 4 days, 8 days,
and 3 months after chemotherapy in patients with breast
cancer. The authors revealed that the coagulation markers
and procoagulants were increased before chemotherapy in
patients who subsequently developed VTE [7]. Additionally,
the authors revealed that aPTT showed a marked decrease
within 24 h of chemotherapy; however, it was more pro-
nounced in patients who subsequently developed VTE. The
reduction in aPTT was maintained for up to 3 months
[7], whereas a marked prolongation of PT was detected
at 8 days and occurred only in patients who subsequently
developed VTE [7]. In a lung cancer study, patients receiving
chemotherapy revealed an early reduction of aPTT (atDays 2,
5, and 7 after treatment) and a slightly later decrease of PT (at
Days 5, 7, and 14 after treatment) [8]. According to these find-
ings, we speculate that there have been some alterations in the
coagulation systems in patients who received chemotherapy.
In colorectal cancer, there is only one small study published
by Ustuner et al. They examined changes in coagulation
parameters in 18metastatic colorectal cancer patients and did
not find any significant changes in platelet count, PT, and
aPTT at baseline and in the subsequent chemotherapy cycles
[5]; however, their study population was small and had no
gender differentiation [5]. In our study, we found a shortened
aPTT after the 8th cycle in men but not in women. However,
this decrease remains within normal limits, and there was no
clinical finding, such as VTE, in any patients for the duration
of our study. Additionally, similar to previous breast cancer
studies, we found minimal INR prolonged from the 0th cycle
of the chemotherapy to the 12th cycle in women; only two
women had Grade 1-2 bleeding during the study, and INR
prolongation was detected after the 12th cycle. We may have
been able to show more INR prolongation if we followed the
patients beyond the 12th cycle, but we did not have prolonged
follow-up results.
In this study, women had greater OS compared withmen,
and this finding may be a reason for men to have more liver
and lung metastases compared with women, so men had a
higher metastatic tumor burden.
In patients with cancer, the major causes are direct
myelotoxicity from chemotherapeutic drugs and cytokine-
mediated inhibition of erythropoiesis [9]. We showed a
drop in Hb after the 4th cycle of FOLFIRI-bevacizumab
chemotherapy in women but not in men. After the 4th cycle,
we did not find any significant change in both men and
women, but we must consider that, during the course of
treatment, especially after the 4th to 6th cycles, some patients
received blood transfusions.
Ustuner et al. did not find any significant changes in D-
dimer and fibrinogen levels after the FOLFIRI-bevacizumab
treatment [5], but we found a nonsignificant reduction in
D-dimer levels in women and a significant decrease after
the 12th cycle in men. This result is interesting because
it reveals that D-dimer has a prognostic value in patients
with colorectal and lung cancers [10]. In addition, Altiay
et al. reported a significant correlation between response to
chemotherapy and D-dimer levels in patients with both local
and advanced lung cancer [11]. In our study, we showed a
significant decrease inD-dimer levels inmen; this reasonmay
be the cause of higher metastatic tumor burden in men, and
thus, after cancer chemotherapy, tumor burden and D-dimer
can decrease; however, there was no significant correlation
with overall survival. We also found a significant increase
in fibrinogen levels in women, but there was no significant
correlation with overall survival.
The major limitation of our study was having limited
number of patients. We have only 34 patients with colorectal
cancer, and we could not show the long-term outcomes such
as VTE and/or bleeding complications. Only two patients
had deep vein thrombosis after the chemotherapy; thus, a
limited number of these patients avoid the statistical analyses.
To our knowledge, there are some reports similar to our
study that revealed the changes of coagulation parameters
with cancer chemotherapy, but our study initially reported
that these changes did not have any negative impact on OS
in patients with colorectal cancer.
In conclusion, FOLFIRI-bevacizumab chemotherapy
altered the coagulation functions according to gender.
Although FOLFIRI-bevacizumab chemotherapy has some
effects, these changes do not have any negative impact on
overall survival and progression-free survival. If chemother-
apy treatment and the possible side effects of FOLFIRI-
bevacizumab are well managed, then alterations of the coag-
ulation cascade will not have any impact on overall survival
and mortality.
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